Navigation Links
US Brachytherapy Market to Reach $1.6 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
Date:6/22/2009

GIA announces the release of a comprehensive global report on Brachytherapy market. Brachytherapy is emerging as an effective treatment option for cancer patients with the market projected to reach $1.6 billion by 2015. Primary growth drivers include rising prevalence of cancer, growing medical awareness, improving success rate of brachytherapy, and advent of advanced radiation technologies.

San Jose, CA (PRWEB) June 22, 2009 -- Rising proportion of cancer population in both developed and developing countries is expected to enhance the demand for brachytherapy for cancer treatment. In particular, brachytherapy has emerged as the effective treatment option for prostate cancer patients, who have failed to achieve desirable results through surgery or external radiation therapy. With long-term clinical data offering support for the effectiveness of brachytherapy in reducing size of the tumor, the therapy is expected to gain strength. With indications for brachytherapy ranging from prostate cancer, head and neck cancer, cervical cancer, and breast cancer to coronary applications, the rapidly aging world population represents a strong demographic growth driver.

The United States represents the largest as well as the fastest growing market for brachytherapy. In the United States, increasing incidence of cancer cases and related mortality rates are contributing to the increasing demand for brachytherapy, as stated in the new report. Rising awareness about risks of surgery and external radiation therapy are fostering advancements in technologies and products for less invasive treatment for cancer. Growing uptake of brachytherapy is also attributed to the increasing success rates of prostate brachytherapy, breast brachytherapy, and head and neck brachytherapy procedures. Driven by the minimally invasive nature of the procedure, Implantable Prostate Seed Therapy is expected to continue posting healthy gains in the market.

Further, balloon brachytherapy for breast cancer treatment is expected to gain rapid acceptance among patients and physicians alike. Post-Operative Brachytherapy market is the fastest growing segment. Growing concerns over rising cancer levels, increasing awareness about adverse effects of EBRT, constant improvements in technologies and devices, and wider acceptance of brachytherapy are expected to boost prospects in the European post-surgical brachytherapy market.

Competition in the brachytherapy market is intensifying, particularly in the implantable prostate seed segment with Oncura Corp., CR Bard, NAS Medical, Theragenics Corporation, and Xoft, competing for a share of the lucrative market. Major players profiled in the report include Best Medical International Inc, BrachySciences Inc, C. R. Bard Inc, Core Oncology, Cytogen Corporation, Cytyc Corporation, Eckert & Ziegler Strahlen- und Medizintechnik AG, International Brachytherapy SA, Oncura, Inc., Theragenics Corporation Sirtex Medical Ltd, Varian Medical Systems Inc, Xoft Inc, among several others.

"Brachytherapy: A US and European Market Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of prevailing market issues and trends, competitive scenario, and recent industry activity in the brachytherapy market. Analytics for the period 2005-2015 provide a comprehensive understanding of markets including the United States and Europe. The markets are analyzed in terms of Number of Procedures (Thousands) and Annual Revenues (US$ Million) for the segments - Implantable Prostate Seed and Post-Surgical Brachytherapy.

For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Brachytherapy_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press (at) StrategyR.com
Web Site http://www.StrategyR.com/

# # #

Read the full story at http://www.prweb.com/releases/brachytherapy/endovascular/prweb2483664.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Varian Medical Systems to Unveil RapidArc(TM) Volumetric Arc Therapy and Other Products Designed to Speed Delivery of Precision Radiotherapy and Brachytherapy
2. FDA Clears New Skin and Surface Treatment Applicator for Use With Xofts Axxent(R) Electronic Brachytherapy (eBx) System
3. R&D Magazine Selects Xoft Axxent(R) Electronic Brachytherapy System as Editors Choice Innovation Award Winner
4. High dosage brachytherapy obtains excellent results in head and neck tumors
5. Prostate Cancer Patients in US and Europe Receive Treatments Using Enhanced Seed Prostate Brachytherapy Software
6. Xoft Receives Health Canada Regulatory Approval for the Axxent(R) Electronic Brachytherapy System
7. Varian Medical Systems Introduces Fast and Precise Brachytherapy Planning System at GEC-ESTRO in Portugal
8. New Fast and Precise Treatment Planning System Among Varian Medical Systems Highlights at American Brachytherapy Society 2009 Meeting
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
US Brachytherapy Market to Reach $1.6 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that ... you are not alone. According to the Center for Disease Control and Prevention (CDC), ... 2 diabetes and certain types of cancer, some of the leading causes of preventable ...
(Date:2/8/2016)... Francisco, CA (PRWEB) , ... February 08, 2016 , ... ... raise $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently retired ... also was the American Cancer Society’s 2015 CEO of the Year , helped ...
(Date:2/8/2016)... ... , ... Discover the Rocky Mountain region’s longest running and impressive garden and ... also get to see the most incredible gardens and home improvement experts that attend ... Colorado Convention Center - 700 14th St. Denver CO, is an exciting event that ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is ... 11th, 2016 in honor of his birthday on February 10th. During this time, ... Trivedi is known by over 250,000 people from over 40 different countries as an ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced today ... the tools and information to lower the costs, and increase the impact of ... providing employee healthcare benefits by as much as 22%:, + Price and ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... N.C. , Feb. 8, 2016  Avista Pharma ... Eric Setzer as Chief Financial Officer (CFO). Mr. ... twenty years of experience in various roles within growing ... Pharma, he served as the Executive Director of Finance ... in Raleigh, NC . Previously, Mr. ...
(Date:2/8/2016)... , Feb. 8, 2016 Velano Vascular, ... experience for hospitalized patients and their practitioners, announced today ... in funding. Velano will use the proceeds from this ... financing completed in January 2015, to support the development ... adult and pediatric populations. Philadelphia ...
(Date:2/8/2016)... -- Vestagen Technical Textiles, Inc., a medical technology company ... other demanding applications, today announced it has named ... Dale Pfost , PhD, who was serving as interim ... Vestagen,s Board of Directors. ® , the ... that combines fluid repellent, antimicrobial and breathability properties. VESTEX ...
Breaking Medicine Technology: